• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Quotient Limited Announces Appointment of Chief Manufacturing Operations Officer

    11/30/21 8:30:00 AM ET
    $QTNT
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QTNT alert in real time by email

    JERSEY, Channel Islands, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mr. Esteban Uriarte as the Company's Chief Manufacturing Operations Officer (CMOO). Mr. Uriarte will assume the responsibilities of CMOO on February 1st, 2022.

    "It is my pleasure to welcome Esteban to the Executive team at this exciting time in our Company's evolution. Esteban brings his experience in leading high-growth teams and unifying manufacturing and supply chain management. As we transition the company from the development phase into commercialization, we will drive scale up in manufacturing to transform the business," said Manuel O. Méndez, Chief Executive Officer of Quotient. 

    Mr. Uriarte brings 30 years of experience in manufacturing and production operations management in the medical devices and pharmaceutical industries. He joins the Company from Ferring Pharmaceuticals where he served as Senior Manufacturing Director responsible for the headquarters site based in Switzerland and the LatAm region. Prior to joining Ferring Pharmaceuticals, he was the Manufacturing Director, Instruments (DACH) at Depuy Synthes, a Johnson & Johnson Company. While there he led 800 employees at five factories and was responsible for defining the global manufacturing strategic initiatives in support of footprint optimization and competitiveness improvement.

    He has held numerous leadership positions at companies such as Vifor Pharma, S.A., Novartis, and Medtronic. Mr. Uriarte holds an MBA in Finance from Inter-American University Metropolitan Campus Puerto Rico, and a BS in Electrical Engineering from the Georgia Institute of Technology.

    "I am very proud and honored to join Quotient at this important phase in the company's journey to transform the diagnostics world and beyond. Helping people improve patient lives has been a strong part of my professional career and I am excited to bring this passion to Quotient. I look forward to working with my new team, address operational excellence, and people development among other themes, to further grow Quotient into a world class supply chain and manufacturing organization and provide our customers with the products and technology they need to serve their patients," said Mr. Uriarte. 

    About Quotient Limited

    Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient's proprietary multiplex microarray technology, offers the world's first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and create operational cost savings to laboratories around the world. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania. The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

    CONTACT: Investor Relations, [email protected]; +41 22 545 52 26



    Primary Logo

    Get the next $QTNT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QTNT

    DatePrice TargetRatingAnalyst
    12/3/2021$4.00 → $3.50Neutral
    Goldman Sachs
    8/6/2021$5.00 → $4.50Neutral
    Goldman Sachs
    More analyst ratings

    $QTNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman Sachs reiterated coverage on Quotient with a new price target

      Goldman Sachs reiterated coverage of Quotient with a rating of Neutral and set a new price target of $3.50 from $4.00 previously

      12/3/21 9:07:16 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Goldman Sachs reiterated coverage on Quotient with a new price target

      Goldman Sachs reiterated coverage of Quotient with a rating of Neutral and set a new price target of $4.50 from $5.00 previously

      8/6/21 8:50:59 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Goldman Sachs initiated coverage on Quotient with a new price target

      Goldman Sachs initiated coverage of Quotient with a rating of Neutral and set a new price target of $5.00

      6/3/21 6:30:51 AM ET
      $QTNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care